文献速递神经肿瘤

端粒酶启动子突变标记IDH突变型与IDH野生型弥漫性胶质瘤中具有相反临床行为的特定分子亚群

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
PubMed 文献 · J Neurosurg · 2017-06-16

该研究纳入299例患者的356个大脑半球弥漫性胶质瘤,按IDH与端粒酶启动子(TERTp)突变状态分为双突变、仅IDH突变、仅TERTp突变和双阴性四个分子亚群。TERTp突变见于38.8%的IDH突变型和70.2%的IDH野生型胶质瘤。在IDH突变型中,双突变亚群较仅IDH突变亚群生存更好且恶性转化发生率更低;在IDH野生型中,仅TERTp突变亚群与更高年龄、更高Ki-67指数及不良生存相关。

要点

  • TERTp突变在IDH突变型胶质瘤中占38.8%,在IDH野生型中占70.2%。
  • IDH突变型中双突变亚群较仅IDH突变亚群生存更好、恶性转化更少。
  • IDH野生型中仅TERTp突变亚群年龄更高、Ki-67更高且生存差。

核心结论

  • 分子亚群划分反映大脑半球弥漫性胶质瘤不同的肿瘤生物学和临床行为。

研究设计与样本

  • 手术队列研究,纳入299例患者共356个大脑半球弥漫性胶质瘤(WHO II、III或IV级)。
  • 按IDH与TERT启动子突变联合状态定义双突变、仅IDH突变、仅TERTp突变和双阴性四个分子亚群。
  • 分析年龄、解剖位置、分子遗传学和生存率的差异。

主要发现

  • TERTp突变见于38.8%的IDH突变型胶质瘤和70.2%的IDH野生型胶质瘤。
  • 在2645个月的累积随访期间,57次复发事件中每例患者的突变状态保持稳定。
  • IDH突变型中,双突变亚群较仅IDH突变亚群生存更好且恶性转化发生率更低。
  • 双突变亚群中96.3%同时存在1p/19q共缺失,所有1p/19q共缺失患者均有TERTp突变。
  • IDH野生型中,仅TERTp突变亚群与更高年龄、更高Ki-67标记指数、原发性胶质母细胞瘤特异性致癌改变及不良生存相关。

关键数值与推荐

  • TERTp突变率:IDH突变型38.8%,IDH野生型70.2%。
  • 双突变亚群中1p/19q共缺失比例为96.3%。
  • IDH突变型中未观察到表皮生长因子受体或磷酸酶及张力蛋白同源物突变,拷贝数变异不常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Recent studies have established that hemispheric diffuse gliomas may be grouped into subsets on the basis of molecular markers; these subsets are loosely correlated with the histopathological diagnosis but are strong predictors of clinical tumor behavior. Based on an analysis of molecular and clinical parameters, the authors hypothesized that mutations of the telomerase promoter (TERTp-mut) mark separate oncogenic programs among isocitrate dehydrogenase 1 and/or 2 (IDH) mutant (IDH-mut) and IDH wild-type (IDH-wt) diffuse gliomas independent of histopathology or WHO grade. METHODS Four molecular subsets of the combined statuses of IDH and TERT-promoter mutations (double mutant, IDH only, TERT only, and double negative) were defined. Differences in age, anatomical location, molecular genetics, and survival rates in a surgical cohort of 299 patients with a total of 356 hemispheric diffuse gliomas (WHO Grade II, III, or IV) were analyzed. RESULTS TERTp-mut were present in 38.8% of IDH-mut and 70.2% of IDH-wt gliomas. The mutational status was stable in each patient at 57 recurrence events over a 2645-month cumulative follow-up period. Among patients with IDH-mut gliomas, those in the double-mutant subset had better survival and a lower incidence of malignant degeneration than those in the IDH-only subset. Of patients in the double-mutant subset, 96.3% were also positive for 1p/19q codeletions. All patients with 1p/19q codeletions had TERTp-mut. In patients with IDH-mut glioma, epidermal growth factor receptor or phosphatase and tensin homolog mutations were not observed, and copy-number variations were uncommon. Among IDH-wt gliomas, the TERT-only subset was associated with significantly higher age, higher Ki-67 labeling index, primary glioblastoma-specific oncogenic changes, and poor survival. The double-negative subset was genetically and biologically heterogeneous. Survival analyses (Kaplan-Meier, multivariate, and regression-tree analyses) confirmed that patients in the 4 molecular subsets had distinct prognoses. CONCLUSIONS Molecular subsets result in different tumor biology and clinical behaviors in hemispheric diffuse gliomas.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Akyerli CB, Yüksel Ş, Can Ö, et al. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg. 2017. PMID: 28621624. doi:10.3171/2016.11.JNS16973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。